Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer.
about
miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expressionCost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer.The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer.APC selectively mediates response to chemotherapeutic agents in breast cancer.Cost of treatment for breast cancer in central Vietnam.The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada.
P2860
Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cost effectiveness of TAC vers ...... f node-positive breast cancer.
@ast
Cost effectiveness of TAC vers ...... f node-positive breast cancer.
@en
type
label
Cost effectiveness of TAC vers ...... f node-positive breast cancer.
@ast
Cost effectiveness of TAC vers ...... f node-positive breast cancer.
@en
prefLabel
Cost effectiveness of TAC vers ...... f node-positive breast cancer.
@ast
Cost effectiveness of TAC vers ...... f node-positive breast cancer.
@en
P2093
P2860
P1433
P1476
Cost effectiveness of TAC vers ...... f node-positive breast cancer.
@en
P2093
P2860
P577
2010-02-01T00:00:00Z